Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications

References

• Ablashi D V, Salahuddin S Z, Josephs S F, Imam F, Lusso P, Gallo R C, Hung C, Lemp J, Markham P D. HBLV (or HHV-6) in human cell lines. Nature 1987; 329: 207
   PubMed Web of Science ®Google Scholar
• Akhyani N, Berti R, Brennan M B, Soldan S S, Eaton J M, McFarland H F, Jacobson M S. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis 2000; 182: 1321–1325
   PubMed Web of Science ®Google Scholar
• Alvarez-Lafuente R, De Las Heras V, Bartolome M, Carcia-Montojo M, Arroyo R. Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study. Brain Pathol 2006; 16: 20–27
   PubMed Web of Science ®Google Scholar
• Alvarez-Lafuente R, De Las Heras V, Bartolome M, Picazo J J, Arroyo R. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol 2004; 61: 1523–1527
   PubMed Web of Science ®Google Scholar
• Braun D K, Dominiguez G, Pellett P E. Human herpesvirus 6. Clin Microbiol Rev 1997; 10: 521–567
   PubMed Web of Science ®Google Scholar
• Campadelli-Fiume G, Mirandola P, Menotti L. Human herpesvirus 6: an emerging pathogen. Emerg Infect Dis 1999; 5: 353–366
   PubMed Web of Science ®Google Scholar
• Challoner P B, Smith K T, Parker J D, MacLeod D L, Coulter S N, Rose T M, Schultz E R, Bennett J L, Garber R L, Chang M, Schad P A, Stewart P M, Nowinski R C, Brown J P, Burmer G C. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995; 92: 7440–7444
   PubMed Web of Science ®Google Scholar
• Chan P K, Ng H K, Hui M, Cheng A F. Prevalence and distribution of human herpesvirus 6 variants A and B in adult human brain. J Med Virol 2001; 64: 42–46
   PubMed Web of Science ®Google Scholar
• Chapenko S, Millers A, Nora Z, Logina I, Kukaine R, Murovska M. Correlation between HHV-6 reactivation and multiple sclerosis disease activity. J Med Virol 2003; 69: 111–117
   PubMed Web of Science ®Google Scholar
• Cuomo L, Trivedi P, Cardillo M R, Gagliardi F M, Vecchione A, Caruso R, Calogero A, Frati L, Faggioni A, Ragona G. Human herpesvirus 6 infection in neoplastic and normal brain tissue. J Med Virol 2001; 63: 45–51
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Bartos A, Egg R, Gilhus N E, Giovannoni G, Rauer S, Sellebjerg F, EFNS Task Force. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol 2006; 13: 913–922
   PubMed Web of Science ®Google Scholar
• DeLorenze G N, Munger K L, Lennette E T, Orentreich N, Vogelman J H, Ascherio A. Epstein-Barr virus and multiple sclerosis. Arch Neurol 2006; 63: 839–844
   PubMedGoogle Scholar
• Derfuss T, Hohlfeld R, Meinl E. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol 2005; 252: 968–971
   PubMed Web of Science ®Google Scholar
• Friedman J E, Lyons M J, Cu G, Ablashi D V, Whitman J E, Edgar M, Koskiniemi M, Vaheri A, Zabriskie J B. The association of the human herpesvirus-6 and MS. Mult Scler 1999; 5: 355–362
   PubMed Web of Science ®Google Scholar
• Friedman J E, Zabriskie J B, Plank C, Ablashi D, Whitman J, Shahan B, Edgell R, Shieh M, Rapalino O, Zimmerman R, Sheng D. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005; 11: 286–295
   PubMedGoogle Scholar
• Grigoriadis N, Hadjigeorgiou G M. Virus-mediated autoimmunity in multiple sclerosis. J Autoimmun Dis 2006; 3: 1–8
   PubMedGoogle Scholar
• Hall C B, Caserta M T, Schnabel K C, Boettrich C, McDermott M P, Lofthus G K, Carnahan J A, Dewhurst S. Congenital infections with human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7). J Pediatr 2004; 145: 472–477
   PubMed Web of Science ®Google Scholar
• Hall C B, Caserta M T, Schnabel K, Long C, Epstein L G, Insel R A, Dewhurst S. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin Infect Dis 1998; 26: 132–137
   PubMed Web of Science ®Google Scholar
• Jääskelainen A J, Piiparinen H, Lappalainen M, Koskiniemi M, Vaheri A. Multiplex-PCR and oligonucleotide microarray for detection of eight different herpesviruses from clinical specimens. J Clin Virol 2006; 37: 83–90
   PubMed Web of Science ®Google Scholar
• Josephs S F, Henry B, Balachandran N, Strayer D, Peterson D, Komaroff A L, Ablashi D V. HHV-6 reactivation in chronic fatigue syndrome. Lancet 1991; 337: 1346–1347
   PubMed Web of Science ®Google Scholar
• Knox K K, Brewer J H, Henry J M, Harrington D J, Carrigan D R. Human herpesvirus 6 and multiple sclerosis: systemic active infections in patients with early disease. Clin Infect Dis 2000; 31: 894–903
   PubMed Web of Science ®Google Scholar
• Levine D P, Lauter C B, Lerner A M. Simultaneous serum and CSF antibodies in herpes simplex virus encephalitis. JAMA 1978; 240: 356–360
   PubMed Web of Science ®Google Scholar
• McDonald W I, Compston A, Edan G, Goodkin D, Hartung H B, Lublin F D, McFarland H F, Paty D W, Polman C H, Reingold S C, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinschenker B Y, Wolinsky J S. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127
   PubMed Web of Science ®Google Scholar
• Moore F GA, Wolfson C. Human herpes virus 6 and multiple sclerosis. Acta Neurol Scand 2002; 106: 63–83
   PubMed Web of Science ®Google Scholar
• Panitch H S. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994; 36: S25–S28, (Suppl)
   PubMed Web of Science ®Google Scholar
• Rotola A, Merlotti I, Caniatti L, Caselli E, Granieri E, Tola M R, Di Luca D, Cassai E. Human herpesvirus 6 infects the central nervous system of multiple sclerosis patients in the early stages of the disease. Mult Scler 2004; 10: 348–354
   PubMedGoogle Scholar
• Salahuddin S Z, Ablashi D V, Markham P D, Josephs S F, Sturzenegger S, Kaplan M, Halligan G, Biberfeld B, Wong-Staal F, Kramarsky P, Gallo R C. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986; 234: 596–600
   PubMed Web of Science ®Google Scholar
• Salonen M JH, Siimes M A, Salonen E-M, Vaheri A, Koskiniemi M. Antibody status to HHV-6 in children with leukaemia. Leukemia 2002; 16: 716–719
   PubMed Web of Science ®Google Scholar
• Soldan S S, Leist T P, Juhng K N, McFarland H F, Jacobson S. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol 2000; 47: 306–313
   PubMed Web of Science ®Google Scholar
• Virtanen J O, Zabriskie J E, Sirén V, Friedman J E, Lyons M J, Edgar M, Vaheri A, Koskiniemi M. Co-localization of human herpesvirus 6 and tissue plasminogen activator in multiple sclerosis brain tissue. Med Sci Monit 2005; 11: BR84–BR87
   PubMed Web of Science ®Google Scholar
• Ward K N, Andrews N J, Verity C M, Miller E, Ross E M. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child 2005; 90: 619–623
   PubMed Web of Science ®Google Scholar
• Ward K N, Gray J J, Fotheringham M W, Sheldon M J. IgG antibodies to human herpesvirus-6 in young children in avidity of antibody correlate with time after infection. J Med Virol 1993; 39: 131–138
   PubMed Web of Science ®Google Scholar
• Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, Kurata T. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988; ii: 1065–1067
   Google Scholar